Clinical trial

Human Menstrual Blood-derived Mesenchymal Stem Cells Transplantation in Treating Type 1 Diabetic Patients

NCT01496339

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

BIOLOGICAL · Unmapped registry intervention MenSCs transplantation Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention exogenous indulin injection daily Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Human Menstrual Blood-derived Mesenchymal Stem Cells Transplantation in Treating Type 1 Diabetic Patients

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE1, PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2012-01-01

PhasePHASE1 / PHASE2

Conditions

Type 1 Diabetes Mellitusverified · MONDO: type 1 diabetes mellitus

Interventions

MenSCs transplantationBIOLOGICAL

exogenous indulin injection dailyDRUG

Sponsors & collaborators

S-Evans Biosciences Co., Ltd.lead sponsor

Zhejiang Universitycollaborator

Wenzhou Medical Universitycollaborator

Zhenjiang First People's Hospitalcollaborator

Mapped research locations

HangzhouZhejiang, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01496339 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.